Literature DB >> 26349191

A NEW OBSERVATION OF 13q DELETION SYNDROME: SEVERE UNDESCRIBED FEATURES.

E Garcia-Rodriguez, E Garcia-Garcia, A Perez-Sanchez, A Pavon-Delgado.   

Abstract

A new observation of 13q deletion syndrome: severe undescribed features: 13q deletion syndrome is characterized by a wide phenotypic spectrum resulting from a partial deletion-of the long arm of chromosome 13. It consists predominantly of mental and motor retardation, craniofacial dysmorphia, growth retardation, and several congenital malformations. We present a new case with 13q deletion syndrome phenotypically characterized by severe major malformations, some of them still undescribed, consisting of left diaphragmatic hernia, right pulmonary sequestration, hypoplastic left heart syndrome, pancreatic agenesis, polysplenia, and catastrophic central nervous system malformations: semilobar holoprosencephaly, occipital myelomeningocele, partial agenesis of the corpus callosum and agenesis of olfactory bulbs. Fluorescence in situ hybridization technique using the probe LSI D13S319 (13q1l4) SO/ LSI 13q34 SG determined partial monosomy of chromosome 13 in 39/100 cells (mosaicism).

Entities:  

Mesh:

Year:  2015        PMID: 26349191

Source DB:  PubMed          Journal:  Genet Couns        ISSN: 1015-8146


  3 in total

1.  Syndromes associated with holoprosencephaly.

Authors:  Paul Kruszka; Maximilian Muenke
Journal:  Am J Med Genet C Semin Med Genet       Date:  2018-05-17       Impact factor: 3.908

2.  Polysplenia syndrome with complex heart disease and jejunal atresia with malrotation in neonate: A case report.

Authors:  Roya Arif Huseynova; Latifa A Bin Mahmoud; Adli Abdelrahim; Majeed A Alroiedy; Ogtay Huseynov
Journal:  Clin Case Rep       Date:  2020-02-28

3.  13q mosaic deletion including RB1 associated to mild phenotype and no cancer outcome - case report and review of the literature.

Authors:  Ilaria Bestetti; Alessandra Sironi; Ilaria Catusi; Milena Mariani; Daniela Giardino; Siranoush Manoukian; Donatella Milani; Lidia Larizza; Chiara Castronovo; Palma Finelli
Journal:  Mol Cytogenet       Date:  2018-09-19       Impact factor: 2.009

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.